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ABSTRACT 
Orally administrable drug delivery vehicles are developed to manage incurable inflammatory 
bowel disease (IBD), however, their therapeutic outc mes are compromised by the side 
effects of systemic drug exposure. Herein, we use hyaluronic acid functionalized porous 
silicon nanoparticle to bridge enzyme-responsive hydrogel and pH-responsive polymer, 
generating a hierarchical structured (nano-in-nano-in-micro) vehicle with programmed 
properties to fully and sequentially overcome the multiple obstacles for efficiently delivering 
drugs locally to inflamed sites of intestine. After o al administration, the pH-responsive 
matrix protects the embedded hybrid nanoparticles containing drug loaded hydrogels against 
the spatially variable physiological environments of the gastrointestinal tract until they reach 
the inflamed sites of intestine, preventing premature drug release. The negatively charged 
hybrid nanoparticles selectively target the inflamed sites of intestine, and gradually release 
drug in response to the microenvironment of inflamed intestine. Overall, the developed 
hierarchical structured and programmed vehicles load, protect, transport and release drugs 
locally to inflamed sites of intestine, contributing to superior therapeutic outcomes. Such 
strategy could also inspire the development of numerous hierarchical structured vehicles by 
other porous nanoparticles and stimuli-responsive materials for the local delivery of various 
drugs to treat plenty of inflammatory gastrointestinal diseases, including IBD, gastrointestinal 
cancers and viral infections. 
 
KEYWORDS 
porous silicon; hybrid nanoparticle; stimuli responsive; targeting; drug delivery 
1. Introduction 
Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease, is 
chronic, relapsing and  medically incurable inflammatory disorders of the intestine [1]. 
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Current available therapies fail to adequately manage the IBD symptoms and are frequently 
associated with severe side effects resulting from systemic drug exposure [2]. One approach 
for more efficacious and safer IBD therapy could be nano/micro-vehicles mediated local drug 
delivery to achieve high drug concentration at the inflamed sites of intestine with minimal 
exposure of healthy intestine or distant tissues [3]. 
Drug delivery vehicles can rather easily reach inflamed intestine for local drug delivery by 
rectal administration which however leads to poor patient compliance [4-6]. For IBD therapy, 
patient compliance can never be overemphasized, which lies in the fact that incurable IBD, 
with most of the patients diagnosed under the age of 30, usually requires lifelong 
administration of drugs to manage symptoms [1]. Oral administration provides the greatest 
degree of patient compliance, however it makes the local drug delivery to inflamed intestine 
extremely challenging, as the corresponding drug delivery vehicles should fulfill multiple 
tasks during their journey from oral cavity to inflamed intestine. Specifically, an optimal 
vehicle should protect the drug and prevent premature drug release in the spatially variable 
physiological environments of the gastrointestinal (GI) tract, selectively target the 
discontinuously distributed inflamed sites of intestine which is usually surrounded by healthy 
intestine, and gradually release drug in response to the microenvironment of inflamed 
intestine.  
To these ends, diverse vehicles, such as polymer particles [7-11], inorganic particles [12, 13], 
liposomes [14], solid lipid particles [15], and hydrogels [11, 16], have been developed. These 
vehicles, although are consisted of novel materials, have not demonstrated the ability to fully 
and sequentially overcome the multiple obstacles for delivering drugs locally to inflamed 
intestine, and their therapeutic outcomes, though encouraging, are still suboptimal and 
significantly compromised by the side effects of systemic drug exposure. Such frustrating 
situation prompts a rethink of the vehicle design strategy solely dependent on material 
composition, and raises attention to the structure design of vehicles for IBD therapy. A 
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hierarchical structured vehicle, with each level in its hierarchy being endowed by rational 
selected material with desired function, holds promise to sequentially tackle each of the 
multiple obstacles for local drug delivery to inflamed intestine. 
Mesoporous nanoparticles, such as porous silicon (PSi), porous silica, halloysite, etc., are 
flexible in the loading/co-loading of drugs with different physicochemical properties [17-23], 
due to their tunable mesoporous structure, large por v lume and high specific surface area 
[24-26], and their hierarchized mesopores make them promising candidates for constructing 
hierarchical structured vehicles [22]. Mesoporous nanoparticles encapsulated in pH-
responsive polymers (two levels of hierarchy) can deliver drugs to the desired segment of 
intestine, however the loaded drugs are usually rapidly released from mesopores nanoparticles 
in an uncontrolled manner due to their freely accessed pores [23, 27, 28]. Hydrogels formed 
by small molecules such as triglycerol monostearate (507 g mol-1) and acorbyl palmitate (AP) 
(415 g mol-1) can encapsulate drugs, and their enzyme-labile bonds enable gradual release of 
drugs in response to degradative enzymes, including matrix metalloproteinases (MMPs) and 
esterases [5, 29, 30], that are up-regulated and releas d in inflamed tissue [5, 29-34]. Inspired 
by these facts, we speculate that AP (molecule size ~2.60 nm [35]) can be co-loaded with 
drugs and further assembled with drugs into hydrogels inside the mesopores of PSi 
nanoparticles. The resultant AP loaded PSi nanoparticles are then expected to gradually 
release drugs in response to the microenvironment of i flamed intestine. 
Furthermore, the versatile surface chemistry of PSinanoparticles makes them a promising 
candidate for targeting the inflamed sites of intestin . Specifically, inflammation of the colon 
mucosa is accompanied by destruction and increased di continuity of the mucus layer [36], 
and in situ accumulation of positively charged proteins including transferrin [14], eosinophil 
cationic protein [37] and bactericidal/permeability-increasing protein [38]. Consequently, 
positive charges build up on the surface of damaged epithelial offer a target for drug delivery 
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vehicles with negative surface charge [5, 14, 39]. Regarding PSi nanoparticles, negative 
charge can be readily obtained on their surface through surface modifications.  
Here, we report a hierarchical structured vehicle (AP@PSi-HA@HPMCAS) based on 
hyaluronic acid (HA) functionalized PSi nanoparticles (PSi-HA), AP and hydroxypropyl 
methylcellulose acetate succinate (HPMCAS) with different solubility profiles depending on 
pH (LF, MF and HF grades) for efficient local drug delivery to inflamed intestine via oral 
administration. Budesonide (BUD), a glucocorticoid for IBD therapy [10], serves as a model 
drug in this study. AP and BUD are co-loaded and in situ gelled inside the mesopores of PSi-
HA hybrid nanoparticles, and then delicately encapsulated in HPMCAS by microfluidic 
technique to form BUD loaded AP@PSi-HA@HPMCAS. We hypothesize that, after oral 
administration, pH-responsive HPMCAS matrix will prevent premature drug release from 
AP@PSi-HA nanoparticles in GI tract until they reach or are close to the inflamed sites of 
intestine. After the dissolution of HPMCAS, negatively charged AP@PSi-HA nanoparticles 
will then selectively bind to the inflamed sites of intestine by electrostatic adhesion, and then 
gradually release drug in response to inflammation due to the enzyme-labile bonds of AP 
(Figure 1). Overall, the hierarchical structured and programmable responsive AP@PSi-
HA@HPMCAS will load, protect, transport and release drugs locally to inflamed sites of 
intestine after oral administration, and contribute to not only superior therapeutic efficacy but 
also considerably reduced systemic drug exposure. 
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Figure 1. Proposed mechanism for the drug delivery by hierarchical structured and 
programed vehicles (AP@PSi-HA@HPMCAS) through GI tract with IBD. HPMCAS (LF, 
MF and HF grades), with different pH dissolution thresholds available, dissolves in specific 
segment of the GI tract. The released AP@PSi-HA nanop rticles with negative surface charge 
do not adhere to the intact mucosa, whereas only adhere to the inflamed mucosa which is 
characterized by depletion of mucus, accumulation of p sitively charged proteins, and 
enhancement of permeability of the epithelial cell layer. The degradative enzymes released by 
the inflamed cells degrade the AP hydrogel, which leads to the release of drug from AP@PSi-
HA. 
2. Results and discussion 
The preparation process of the hierarchical structued and programmable responsive 
BUDAP@PSi-HA@LF for delivering BUD is schematically i lustrated in Figure 2a. HA was 
conjugated onto the surface of carboxyl-terminated PSi nanoparticles (Figure 2b, Figure S1a) 
using spermine (SPM) as linker via 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide/N-
hydroxysuccinimide (EDC/NHS) reaction to form PSi-HA hybrid nanoparticles (Figure 2c, 
Figure S1b) with negative surface charge (–30 ± 2 mV) for targeting inflamed intestinal 
mucosa and high colloidal stability (Figure 2d–e) for microfluidic encapsulation. The 
successful conjugation of HA onto PSi was indicated by the particle size and surface charge 
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variations after each reaction step (Figure 2f), and confirmed by the appearance and 
enhancement of amide I band at 1642 cm−1  in the  Fourier-transform infrared spectroscopy 
(FTIR) spectra (Figure 2g) after each reaction step in addition to the inheritance of 
characteristic bands of PSi, SPM and HA in PSi-HA (Figure 2g). The amount of HA in PSi-
HA was determined to be 12.5 ± 1.3 wt% by thermogravimetric analysis (Figure S2). Small 
molecular BUD and AP were co-loaded into PSi-HA at 65 °C, and then were cooled down to 
room temperature for the in situ gelation of AP and BUD inside PSi-HA to form 
BUDAP@PSi-HA, making use of the readily temperature controlled gelation behavior of AP 
(Figure S3). BUDAP@PSi-HA was subsequently encapsulated in LF to form the final 
hierarchical structured BUDAP@PSi-HA@LF particles (35 ± 1 µm) (Figure 2h) using 
droplet microfluidics. The obtained uniform particle size is beneficial for achieving controlled 
and reproducible drug release profiles [40]. The successful co-loading of BUD and AP in PSi-
HA and encapsulation of BUDAP@PSi-HA in LF were confirmed by FTIR (Figure S4). The 
loading degree of BUD in BUDAP@PSi-HA and BUDAP@PSi-HA@LF was 24.5 ± 0.1 % 
and 3.8 ± 0.3 %, respectively. 
The distribution of BUDAP@PSi-HA nanoparticles in the LF matrix was evaluated by 
confocal microscopy. To enable the visualization, PSi-HA was conjugated with fluorescein 
isothiocyanate (FITC, green) and LF matrix was labeled with tetramethylrhodamine (TRITC, 
red). The confocal images indicated that PSi-HA was evenly distributed in the LF matrix 
(Figure 2h), and scanning electron microscopy (SEM) image showed that BUDAP@PSi-
HA@LF had smooth surface and well defined spherical sh pe (Figure 2h). 
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Figure 2. a) Fabrication process of hierarchical structured an  programmable responsive 
vehicles (BUDAP@PSi-HA@LF). b–c) Transmission electron microscopy (TEM) image of b) 
PSi and c) PSi-HA. d) Size and e) polydispersity index (PDI) of PSi and PSi-HA dispersing in 
Milli-Q water during 2 h, demonstrating the high colloidal stability of PSi-HA over time. Data 
represent mean ± SD. (n = 3). f) Size, PDI, and surface zeta potential of PSi, PSi-SPM and 
PSi-HA. g) FTIR of PSi, SPM, PSi-SPM, HA and PSi-HA. h) The monodispersity of the 
fabricated BUDAP@PSi-HA@LF was studied by confocal microscopy and SEM. PSi-HA 
was conjugated with FITC and LF layer was labelled with TRITC. The confocal images 
showed the FITC (green), TRITC (red) and the overlay (yellow) channels. The surface of the 
particles was observed by SEM. 
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The developed hierarchical structured AP@PSi-HA@LF was then investigated for its 
programmable responsive properties. The pH-responsive dissolution behavior of protective 
matrix was firstly evaluated by immersing PSi-HA@LF in aqueous buffer solutions at various 
pH values, starting from pH 1.2 to 5.5. PSi-HA@LF was intact at pH < 5.5, and immediately 
began to dissolve at pH 5.5 (Figure 3a), while particles made by MF and HF only started to 
dissolve when pH reached 6.0 and 6.8, respectively [23, 41]. To further evaluate the pH-
responsive properties of PSi-HA@HPMCAS (LF, MF or HF), BUD solely was loaded in PSi-
HA@HPMCAS (LF, MF or HF). BUD@PSi-HA@LF, BUD@PSi-HA@MF and BUD@PSi-
HA@HF only began to release BUD when the pH reached 5.5, 6.0 and 6.8, respectively, and 
the release was nearly complete within 30 min (Figure S5) due to the short disintegration 
time (~10 min according to the manufacturer) of HPMCAS (LF, MF and HF). The precisely 
pH-trigged drug release behaviors of PSi-HA@HPMCAS suggest its potential to release BUD 
at specific segment of the intestine by the flexible selection and combination of LF, MF and 
HF. The intestinal pH of mice is lower than that of human [42], therefore, LF rather than MF 
or HF was used for the animal experiments.  
The enzyme-responsive properties of drug loaded AP@PSi-HA@LF were firstly investigated 
in buffer solutions. In contrast to the rapid releas  of BUD from PSi-HA@LF, AP@PSi-
HA@LF only slightly released BUD (6.5% at 6 h) in the absence of lipase even though pH 
reached 5.5. With increasing concentration of lipase, gradual release of BUD from AP@PSi-
HA@LF was accelerated, i.e., 8.5%, 75.6% and 88.4% at 6 h for 0.01, 1 and 100 U/mL lipase, 
respectively (Figure 3b), suggesting AP@PSi-HA@LF can adjust drug release to match the 
disease activity at inflamed intestine. IBD is characterized by variable disease activity over 
time with flares and periods of low disease activity. A disease activity-dependent drug 
delivery vehicle is likely to avoid sub- or supra-therapeutic drug concentrations locally during 
periods of high or low disease activity, respectively, resulting in maximized therapeutic 
efficacy and minimized systemic drug exposure [30]. 
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Overall, BUDAP@PSi-HA@LF exhibited pH and enzyme programmable responsive drug 
release behaviors. To simulate drug release from AP@PSi-HA@LF under inflammatory 
conditions, BUDAP@PSi-HA@LF was incubated with supernatant collected from human 
macrophages cultured with or without lipopolysaccharide (LPS). In comparison to 
unstimulated macrophages, macrophages activated by LPS enhanced the enzymatic activities 
in the supernatant [5, 30, 32, 33], which resulted in significantly increased BUD release 
(Figure 3c). The above enzyme-responsive drug release behaviors suggest that AP@PSi-
HA@LF would preferentially release BUD at the sites of inflamed intestine rather than 
healthy intestine or distant healthy tissues, and therefore reduce systemic drug exposure which 
often causes side effects. 
Since AP@PSi-HA@LF is designed for oral drug delivery, two human intestinal epithelial 
cell lines, Caco-2 clone C2Bbe1 and HT29-MTX, were us d to assess its safety. After 24 h 
incubation with both cell lines, there was no evidence of cytotoxicity for PSi-HA@LF and 
BUDAP@PSi-HA@LF as well as their components, i.e., PSi-HA, AP and BUD (Figure S6, 
Figure S7 and Figure S8). 
The therapeutic efficacy and systemic absorption of BUD delivered by AP@PSi-HA@LF 
were firstly studied using in vitro IBD model. The in vitro IBD model consisted of triple co-
cultured cells including intestinal epithelial cells, human blood-derived macrophages and 
dendritic cells that were stimulated by pro-inflammatory cytokine interleukin-1β (IL-1β) in 
combination with lipopolysaccharide (LPS) (Figure S9). The experimental timeline of setting 
up the in vitro IBD model and subsequent testing of BUD formulations is shown in Figure 
S10. As an indication of the integrity and permeability of the monolayer, transepithelial 
electrical resistance (TEER) value was monitored during the experiment period. Compared to 
free BUD and BUD@PSi-HA@LF, BUDAP@PSi-HA@LF treatment recovered the TEER to 
the highest level, and was significantly higher at d y 1 (Figure S11). Furthermore, as a 
marker of inflammation, IL-8 release from the cells under the treatment of different BUD 
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formulations was measured. BUDAP@PSi-HA@LF treatment significantly reduced the IL-8 
production to the lowest level (Figure 3d), which indicates a prolong therapeutic effect of 
programmable responsive BUDAP@PSi-HA@LF than free BUD and BUD@PSi-HA@LF, 
mainly owing to the sustained drug release provided by the remaining enzyme-responsive 
BUDAP@PSi-HA on monolayers. 
Since AP@PSi-HA@LF is designed for local delivery of BUD for precise therapy of IBD via 
oral administration, its effects on systemic drug absorption is another important evaluation 
index. AP@PSi-HA@LF significantly reduced the permeability of BUD across the 
monolayers in comparison to free BUD and PSi-HA@LF in both inflamed and healthy 
conditions (Figure 3e–f), which is attributed to the much slower release of BUD from 
AP@PSi-HA@LF (Figure 3b–c). Thus, delivering drug by hierarchical structured and 
programmable responsive AP@PSi-HA@LF will result in a major reduction in systemic drug 
absorption and consequently reduce the possibility of side effects. 
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Figure 3. a) SEM images of PSi-HA@LF after immersion in buffer solutions at pH 1.2 and 
5.0 for 2 h, and at pH 5.5 for 5 min and 2 h. b) pH and enzyme sequentially responsive BUD 
release from AP@PSi-HA@LF in a series of pH buffers at 37 °C. Enzyme (lipase; 0.01, 1, 
and 100 U/mL) was added at 3 h. Data are means ± SD (n = 3). c) BUD release from 
AP@PSi-HA@LF upon incubation for 24 h at 37 °C with culture supernatant from LPS 
activated human macrophages. Data are means ± SD (n = 3). d) Normalized IL-8 release of 
Caco-2 clone, macrophages and dendritic cells triple co-culture IBD model after induction of 
inflammation and subsequent treatment with various BUD formulations and blank vehicle 
control (without BUD). Data are means ± SD (n = 4). e) Permeation profiles of BUD across 
the Caco-2 clone monolayers co-cultured with macrophages and dendritic cells in both 
healthy and inflamed conditions. f) Apparent permeability coefficients (Papp) of BUD 
calculated from the permeation profiles of BUD. Data re means ± SD (n = 3). 
 
To maximize the therapeutic efficacy and minimize th systemic exposure of drug delivered 
by AP@PSi-HA@LF in vivo, AP@PSi-HA@LF should selectively adhere to the inflamed 
sites of intestine. We hypothesize that the negative surface charge of AP@PSi-HA (–32 ± 1 
mV) will facilitate its targeting to the inflamed intestinal epithelium, where positively charged 
proteins are accumulated [14, 37, 38]. To verify this ypothesis, the adhesion properties of 
AP@PSi-HA were firstly tested in vitro using synthetic surfaces. BUDAP@PSi-FITC/HA (–
33 ± 2 mV) was incubated on glass slides or polystyrene plates coated with human transferrin 
(positively charged) or porcine mucin (negatively charged), simulating inflamed and healthy 
epithelium, respectively [5]. Compared to mucin coated surfaces, transferrin coated surfaces 
retained much more particles (Figure 4a) and showed a 14.9-fold higher fluorescence signal 
(Figure 4b) after extensive washing with phosphate buffered saline (PBS). In another control 
experiment, BUDAP@PSi-FITC/HA was incubated with a cationic polyethylenimine (PEI) 
solution to convert its surface charge from negative to positive (35 ± 2 mV). As predicted, this 
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charge conversion abolished the preferential adhesion of BUDAP@PSi-HA to transferrin 
coated surfaces and enhanced its adhesion to the mucin coated surfaces (Figure S12). 
Following the promising results in vitro, we further examined the targeting of AP@PSi-HA to 
inflamed mucosa using in vivo IBD model, i.e., dextran sulfate sodium (DSS)-induced mouse 
colitis model. Mice with colitis and normal mice received a single dose of BUDAP@PSi-
Cy7/HA@LF (–31 ± 1 mV for BUDAP@PSi-Cy7/HA) (for IVIS imaging) or BUDAP@PSi-
FITC/HA@LF (for confocal imaging) by oral gavage. Mice with colitis showed significantly 
greater retention of fluorescence than normal mice aft r the administration of BUDAP@PSi-
Cy7/HA@LF for 2 h and 5 h (Figure 4c and Figure 4d). Confocal microscopy images of 
distal end of colon sections (Figure 4e) showed the targeting of BUDAP@PSi-FITC/HA to 
the inflamed sites of colon. Together with the pH and enzyme responsive properties of 
AP@PSi-HA@LF, we would expect that hierarchical structured AP@PSi-HA@LF can 
efficiently deliver BUD locally to inflamed sites of intestine by executing its programmed 
functions in the GI tract suffered with IBD. 
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Figure 4. a) Confocal microscopy images and b) fluorescence i t nsities (quantified by 
microplate reader) of BUDAP@PSi-FITC/HA after incubation with uncoated, mucin coated 
(simulating healthy epithelium) or transferrin coated (simulating inflamed epithelium) 
surfaces for 1 h at 37 °C, followed by washing with PBS for 3 times. Data are means ± SD (n 
= 6). c–d) Mice with DSS-induced colitis and normal mice were orally administrated with 
BUDAP@PSi-Cy7/HA@LF. c) The living mice were imaged using IVIS fluorescence 
imaging system after 2 h and 5 h, respectively. d) The mice were sacrificed 5 h after 
administration, and the intestines were dissected and imaged using IVIS fluorescence imaging 
system. The total fluorescence intensity was determined in a standard-size region of interest 
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(ROI) drawn around the whole intestine (c) or colon (d). (c) and (d) share the same radiance 
scale bars. Data are means ± SD (n = 3). e) Immunofluorescence images of distal end of colon 
dissected from normal mice and mice with colitis 5 h after orally administrated with 
BUDAP@PSi-FITC/HA@LF. Nucleus and macrophages were stained by DAPI and F4/80, 
respectively. All the images have the same scale bar. 
 
We then tested the in vivo therapeutic efficacy of BUD delivered by hierarchical structured 
and programmable responsive AP@PSi-HA@LF in DSS-induce  mouse colitis model. BUD 
was studied at low dose (L, 0.5 mg/kg) and high dose (H, 1.5 mg/kg), respectively. Free BUD 
(FBUDL and FBUDH), blank vehicles without BUD, i.e., AP@PSi-HA@LF (PL and PH) 
and pH-responsive BUD@PSi-HA@LF (BUDL and BUDH) were employed as controls to 
demonstrate the therapeutic benefits of hierarchical structured and programmable responsive 
BUDAP@PSi-HA@LF (BUDAPL and BUDAPH). After induction of the colitis for 7 d, the 
treatment was conducted by daily oral gavage for 7 d, during which the body weight of colitis 
mice gradually decreased (Figure 5a). Whereas treatment with BUDAP@PSi-HA@LF 
(BUDAPL and BUDAPH) significantly mitigated weight loss as compared to free BUD 
(FBUDL and FBUDH) and BUD@PSi-HA@LF (BUDL and BUDH) (Figure 5a). The 
severity of colitis was assessed by disease activity ndex (DAI). Interestingly, all treated 
groups showed significantly reduced DAI after treatment for 7 d as compared to colitis group, 
and the minimal DAI was found for BUDAP@PSi-HA@LF (BUDAPL and BUDAPH) 
(Figure 5b). Besides, BUDAPH notably preserved colon length when compared to FBUDH 
and BUDH (Figure S13). Furthermore, the levels of typical proinflammatory cytokines 
including IL-1β and IL-6 were quantified. Colitis mice exhibited elevated levels of both IL-1β 
and IL-6 than normal mice (Figure 5c–d). Overall, the levels of IL-1β and IL-6 decreased 
after treatment with BUD formulations, and the group of mice treated with BUDAP@PSi-
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HA@LF showed the lowest concentration of IL-1β and IL-6 in comparison to the other 
treated groups. 
Additional information was obtained by examining and scoring hematoxylin and eosin (H&E) 
stained histological sections of distal end (Figure 5e–f) of colon tissues. The colitis was 
characterized by superficial erosions, depletion of goblet cells, infiltration of the colon lamina 
propria with inflammatory cells, and crypt hypertrophy [5, 9]. Disease severity was 
significantly reduced in mice treated with BUD@PSi-HA@LF (BUDL and BUDH) and 
BUDAP@PSi-HA@LF (BUDAPL and BUDAPH) (Figure 5e), and representative images 
(Figure 5f) demonstrate that treatment with BUDAP@PSi-HA@LF offered the best 
improvement in pathological injuries, which was also confirmed by TUNEL staining (Figure 
S14). Overall, BUD delivered by hierarchical structured and programmable responsive 
AP@PSi-HA@LF exhibits superior therapeutic efficacy than free BUD and BUD delivered 
by pH-responsive PSi-HA@LF, which was attributed to the protection of BUDAP@PSi-HA 
in GI tract by LF, targeting of BUDAP@PSi-HA to the inflamed sites of colon and 
subsequent prolonged release of BUD from AP@PSi-HA in response to the 
microenvironment of inflamed intestine. 
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Figure 5. Therapeutic efficacy of various BUD formulations on IBD model of DSS-induced 
colitis in mice. a) Body weight and b) DAI of mice during 7 d of induction of colitis model 
and 7 d of treatment. Data were normalized as a percentage of the body weight at day 0. c–d) 
The levels of c) IL-1β and d) IL-6 after 7 d of treatment. e) Histopathology score of the distal 
end of colon after 7 d of treatment. f) Representative H&E histology images of the distal end 
of colon after 7 d of treatment. All the images have the same scale bar. Data are means ± SD 
(n = 5). *p < 0.05, **p < 0.01 and ***p < 0.001 versus the colitis group. 
3. Conclusions 
In summary, we have developed a hierarchical structu ed and programmable responsive 
AP@PSi-HA@HPMCAS vehicle for efficient local drug delivery to inflamed sites of 
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intestine in IBD therapy via oral administration. The prepared vehicles showed well-defined 
spherical shape and uniform particle size. The pH-responsive matrix protects the drug and AP 
co-loaded PSi nanoparticles against the complex environment of the GI tract before reaching 
the desired segment of intestine, and prevents premature drug release. The negatively charged 
AP@PSi-HA nanoparticles selectively target the inflamed sites of intestine, and locally 
release the drug in response to the inflammation gradually over a prolonged duration. 
Compared to free drug and conventional pH-responsive particles, drug delivered by 
hierarchical structured and programmable responsive AP@PSi-HA@HPMCAS exhibit 
superior therapeutic efficacy and significantly reduced systemic drug exposure, substantiating 
the importance of engineering hierarchical structured and programmed vehicles for delivering 
drugs locally to inflamed sites of intestine. 
4. Materials and methods 
4.1. Preparation of PSi nanoparticles 
Electrochemical anodization method was used to prepare undecylenic acid modified thermally 
hydrocarbonized PSi (UnTHCPSi), as described in detail elsewhere [43]. Briefly, 
monocrystalline p+-type Si (100) wafers (0.01‒ .02 Ω cm resistivity) were electrochemically 
anodized in a 1:1 (v/v) aqueous hydrofluoric acid (38%)–ethanol electrolyte by applying 
repeated low and high current density pulsed etching profile. The resulting PSi with high 
porosity fracture planes and hydrogen-terminated surface was subsequently detached from the 
substrate as free-standing multilayer films by abruptly increasing the current density to 
electropolishing region. Thermal hydrocarbonization f the PSi films was performed by 
exposing them to a 1:1 (v/v) N2/acetylene (C2H2) flow (1 L min
−1) for 15 min at room 
temperature, followed by a heat treatment for 15 min at 500 °C. The obtained THCPSi films 
were then treated with 10-undecenoic acid for 16 h at 120 °C. The UnTHCPSi films were 
finally wet ball milled to produce nanoparticles and separated using centrifugation to obtain 
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the final PSi nanoparticles with desired particle size. Nitrogen adsorption–desorption 
isotherms of PSi nanoparticles were measured at 77 K on a gas adsorption analyzer 
(Micromeritics TriStar 3000, USA). The specific surface area was determined from the 
adsorption branch of the nitrogen isotherm using the Brunauer-Emmett-Teller (BET) theory 
[44], and the pore volume was determined as the total adsorbed amount at a relative pressure 
(p/p0) of 0.97. The average diameter of the pores was 4×pore volume/specific surface area. 
The specific surface area and pore volume of PSi nanop rticles used in this study were 305 ± 
10 m2/g and 0.89 ± 0.01 cm3/g, respectively. The average diameter of the pores was calculated 
to be 11.6 ± 0.4 nm. 
4.2. Preparation of HA 
The aqueous solution of HA sodium salt (Sigma-Aldrich, USA) was dialyzed against 0.01 M 
HCl for 24 h and then against Milli-Q water for an dditional 24 h to convert HA from its 
sodium salt form to acid form. The acid form of HA was recovered by lyophilization [45]. 
4.3. Preparation of PSi-HA nanoparticles 
PSi nanoparticles were covalently conjugated with SPM using the EDC/NHS reaction. 
Typically, 1 mg PSi nanoparticles were dispersed in 1 mL of anhydrous dimethylformamide 
(DMF) (Sigma-Aldrich, USA). Then 4 µL (22.6 µmol) EDC (Sigma-Aldrich, USA) and 3 mg 
(26.1 µmol) NHS (Sigma-Aldrich, USA) were added into the above suspension and stirred 
overnight. Subsequently, 20 mg (98.8 µmol) SPM (ACROS Organic, UK) were added and 
stirred overnight. The prepared PSi-SPM nanoparticles were collected by centrifugation and 
extensively washed with DMF for 3 times. 4 mg HA were dissolved in 1 mL anhydrous 
dimethyl sulfoxide (DMSO) (Sigma-Aldrich, USA). Then 2.8 µL EDC and 1.8 mg NHS were 
added and stirred for 2 h. Afterwards, 1 mg PSi-SPM nanoparticles were dispersed into the 
above solution and stirred overnight. The obtained PSi-HA nanoparticles were collected by 
centrifugation and extensively washed with Milli-Q water for 5 times. 
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The amount of HA on the surface of PSi nanoparticles was estimated using TGA 7 
thermogravimeter (PerkinElmer, USA). The samples were heated from room temperature to 
850 °C at a heating rate of 20 °C /min under a 200 mL/min N2 flush. The measurements were 
done in triplicates. 
4.4. Loading of BUD and AP in PSi-HA nanoparticles 
BUD and AP were co-loaded into PSi-HA nanoparticles using an immersion method. BUD 
and AP were dissolved together in a mixture of ethanol–H2O (1:1 v/v) at a concentration of 25 
and 75 mg/mL, respectively, at 65 °C. 10 mg PSi-HA were added into 2 mL of the above 
solution and stirred for 3 h at 65 °C. Afterwards, the BUD and AP loaded PSi-HA 
(BUDAP@PSi-HA) nanoparticles were collected by centrifugation for 3 min using pre-
warmed rotor, and then were allowed to cool down to room temperature for the gelling of AP 
before washing by Milli-Q water. The procedures to prepare PSi-HA loaded with BUD only 
(BUD@PSi-HA) and PSi-HA loaded with AP only (AP@PSi-HA) were the same as 
BUDAP@PSi-HA, and the concentration of BUD and AP in ethanol–H2O (1:1 v/v) was 25 
and 75 mg/mL, respectively. 
4.5. Fabrication of flow-focusing device for microfluidics 
Borosilicate glass cylindrical capillaries (World Precision Instruments, USA) and glass slides 
were used to assemble the microfluidic flow-focusing device [23, 27]. The inner capillary had 
an outer diameter of 1000 µm. Firstly, the inner capillary was tapered using a micropipette 
puller (P-97, Sutter Instrument, USA), and then enlarged to 350 µm. Subsequently, the 
tapered capillary was inserted into the right end of the outer capillary with an inner diameter 
of 1120 µm. Two syringes were linked to the microfluidic device using polyethylene tubes to 
allow the independent injection of the inner and outer fluids controlled by pumps (PHD 2000, 
Harvard Apparatus, USA). A transparent epoxy resin (5 minute® Epoxi, Devcon, USA) was 
used to seal the microfluidic device where required. 
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4.6. Fabrication of pH-responsive microparticles 
PSi-HA nanoparticles were encapsulated in pH-sensitive HPMCAS (ShinEtsu, Japan) to form 
PSi-HA@HPMCAS microparticles using water-in-oil-in-water (W/O/W) double emulsion 
through a microfluidic flow-focusing device. Three grades (LF, MF and HF) of HPMCAS, 
which vary in their pH-dependent solubility, were used. The LF, MF and HF grades of 
HPMCAS dissolve at pH ≥ 5.5, 6.0 and 6.8, respectively. For the microfluidic encapsulation, 
HPMCAS (LF, MF or HF) was dissolved in ethyl acetat (EA) at a concentration of 10 mg 
mL−1. 2 mg PSi-HA nanoparticles were dispersed in 100 µL Milli-Q water and added 
dropwise into 1 mL HPMCAS (LF, MF or HF) solution uder sonication (Sonics, Sonics & 
Materials Inc, USA) to produce the primary emulsion (W/O) which served as the inner 
dispersed fluid. 2% w/v P-407 (BASF, Germany) aqueous solution (pH 5) was used as the 
outer continuous fluid to obtain a stable W/O/W emulsion. The inner fluid (3.5 mL h−1) was 
focused by the outer fluid (15 mL h−1), and the formed droplets were collected in 1% w/vP-
407 aqueous solution (pH 5). Afterwards, the produce  PSi-HA@HPMCAS (LF, MF or HF) 
microparticles were collected by centrifugation. 
4.7. Fabrication of BUD and/or AP loaded microparticles 
BUDAP@PSi-HA@LF, BUD@PSi-HA@HPMCAS (LF, MF or HF) and AP@PSi-HA@LF 
microparticles were prepared using BUDAP@PSi-HA, BUD@PSi-HA and AP@PSi-HA 
nanoparticles, respectively, under the same condition as the PSi-HA@LF microparticles. The 
loading degrees of BUD in particles were determined by stirring the particles in a mixture of 
PBS and acetonitrile (1:1 v/v) to dissolve the HPMCAS matrix and AP hydrogel, and to 
release all the loaded BUD. The amount of BUD was quantified by Agilent 1100 high 
performance liquid chromatography (HPLC) (Agilent Technologies, USA) with a mobile 
phase composed of phosphoric acid (0.1%, pH 3.2) and acetonitrile (volume ratio 52:48) at a 
flow rate of 1.4 mL min−1 at 25 °C. The wavelength used for BUD quantification was 244 nm. 
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A Discovery® C18 column (4.6 × 150 mm, 5 µm, Supelco Analytical, USA) was used as 
stationary phase and the injection volume of the samples was 20 µL. 
4.8. Physicochemical properties of nanoparticles and microparticles 
The particle size, PDI and surface charge of nanoparticles were determined by Zetasizer Nano 
ZS (Malvern Instruments Ltd, UK) in Milli-Q water with pH adjusted to 7.4 by HCl/NaOH. 
The stability of nanoparticles was evaluated by following their changes on size and PDI after 
incubation of 200 µg/mL of nanoparticles with Milli-Q water (pH 7.4) during 2 h. Samples 
were withdrawn at 15, 30, 60, 90 and 120 min, and diluted in Milli-Q water (pH 7.4) for 
measuring the size and PDI. Milli-Q water was used for stability test as it was used for 
dispersing the PSi-HA nanoparticles during the microfluidic fabrication of PSi-
HA@HPMCAS. 
The structure of nanoparticles and morphology of microparticles were observed by TEM 
(JEOL 1400, Japan) and SEM (Hitachi S-4800, Japan), respectively. The microparticles were 
platinum sputtered before imaging. The particle size of microparticles was determined using 
Image J (NIH, USA), and at least 100 particles were analyzed. The chemical composition of 
the nanoparticles and microparticles was characterized by FTIR (Vertex 70, Bruker, USA). 
The samples were mixed with KBr (FTIR grade, Sigma-Aldrich, USA) and pressed into 
pellets. The pellets consisted of 1 mg of sample and 200 mg of KBr. The FTIR spectra were 
recorded in the range of 4000–400 cm-1 with a resolution of 4 cm-1 using OPUS 5.5 software. 
For studying the distribution of PSi-HA nanoparticles within the LF microparticles, PSi-HA 
was labelled with FITC (Thermo Fisher Scientific, USA) as described in following sections, 
and the LF polymer was mixed with TRITC (Thermo Fisher Scientific, USA) at a mass ratio 
of 100 to 1. After microfluidic fabrication as described above, the produced PSi-HA@LF 
microparticles were placed into 35 mm Petri dish (MatTek, USA), and imaged using confocal 
microscope (Leica SP5 II HCS A, Germany). 
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4.9. pH-responsive dissolution behavior of microparticles 
To investigate the pH-responsive dissolution behavior of the prepared PSi-HA@LF 
microparticles, they were mounted onto stubs using carbon tape, and then treated with buffer 
solutions at different pH values (1.2 and 5.0) for 2 h and at pH 5.5 for 5 min and 2 h. The 
excess solutions were removed and the samples were dri d at room temperature for 24 h. The 
microparticles without any treatment were used as a control. All samples were platinum 
sputtered before imaging. 
4.10. pH-responsive drug release study 
The pH-responsive drug release profiles of BUD@PSi-HA@HPMCAS (LF, MF and HF) 
were studied in continuous gradient pH media at 37 °C with shaking at 150 rpm. Free BUD 
was used as control group. Samples containing 50 µg BUD were added into 50 mL media at 
pH 1.2, and the pH was then gradually increased to 5.0, 5.5, 6.0 and 6.8. At predetermined 
time intervals, 200 µL of sample were withdrawn from each sample and the rel ase media 
was replaced with 200 µL of fresh media. Samples were firstly centrifuged (16100 g, 3 min), 
and then the drug concentrations in the supernatant were quantified by HPLC. 
4.11. Enzyme-responsive drug release study 
The enzyme-responsive drug release profiles of BUDAP@PSi-HA@LF were studied in 
continuous gradient pH media without and with 0.01, 1 or 100 U/mL of Thermomyces 
lanuginosus lipase (Sigma-Aldrich, USA) at 37 °C with shaking at 150 rpm. BUD@PSi-
HA@LF and free BUD were used as control groups. Samples containing 50 µg BUD were 
added into 50 mL media at pH 1.2, and the pH was then gradually increased to 5.0, 5.5, 6.0 
and 6.8. Lipase was added when pH was increased to 5.0. At predetermined time intervals, 
200 µL of sample were withdrawn from each sample and the release media was replaced with 
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200 µL of fresh media. Samples were firstly centrifuged (16100 g, 3 min), and then the drug 
concentrations in the supernatant were quantified by HPLC.  
BUD release was also studied in culture supernatant from human macrophages. The method 
for obtaining macrophages was described in detail in ater sections. Macrophages were 
cultured without and with 0.1 µg/mL lipopolysaccharide (LPS) (Sigma-Aldrich, USA), and 
supernatant was collected after 4 and 24 h. 10 mg BUDAP@PSi-HA@LF were suspended in 
1 mL of Milli-Q water (pH 5.0), and 20 µL of this suspension were added to 1 mL of 
supernatant from unstimulated or LPS-stimulated macrophages. After incubation at 37 °C for 
24 h, samples were centrifuged at 16100 g for 5 min, and BUD concentration in the 
supernatant was measured by HPLC.  
4.12. Cell line culture 
Human colon carcinoma (Caco-2), Caco-2 clone C2Bbe1 and human colon adenocarcinoma 
(HT29-MTX) cells were separately cultured in Dulbecco’s modified Eagle medium (DMEM) 
(HyClone, USA) with 4.5 g L−1 glucose, supplemented with 10% fetal bovine serum (Gibco, 
Invitrogen, USA), 1% nonessential amino acids, 1% L-glutamine, penicillin (100 IU mL−1) 
and streptomycin (100 mg mL−1) (all from HyClone, Logan, UT). The cells were maint ined 
at 37 °C with an atmosphere of 5% CO2 and 95% relative humidity, and the culture media 
were changed every other day. Prior to each test, the cells were harvested using 0.25% (v/v) 
trypsin–ethylenediaminetetraacetic acid (EDTA)–phosphate buffer solution. 
4.13. Macrophages and dendritic cells culture 
Buffy coats were processed by Ficoll-Paque gradient c rifugation to obtain the peripheral 
blood mononuclear cells (PBMCs). Macrophages and deritic cells were differentiated from 
CD14+ monocytes that were isolated from PBMCs using CD14 MicroBeads (Miltenyi Biotec). 
These cells were cultured with macrophage medium (RPMI 1640 medium with 1% L-
glutamine (HyClone, USA), supplemented with 10% human serum AB (BioWest, France), 
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1% nonessential amino acids, penicillin (100 IU mL−1) and streptomycin (100 mg mL−1), and 
1% sodium pyruvate (Gibco, UK)). Macrophages were obtained after cultivation for 6 d with 
macrophage medium, while dendritic cells were obtained after cultivation for 6 d with 
macrophage medium supplemented with 80 ng/mL recombinant human GM-CSF (Peprotec, 
USA) and 80 ng/mL recombinant human IL-4 (Peprotec, USA) [46]. 
4.14. Cytotoxicity studies 
100 µL Caco-2 clone and HT29-MTX cells were separately seeded in 96-well plates at a 
density of 2 × 105 cells mL-1. After the cells were left to attach for 24 h, theculture medium 
was discarded and the cells were washed with 100 µL fresh 1× Hank's Balanced Salt Solution 
(HBSS)−HEPES (pH 7.4). Then PSi, PSi-HA and PSi-HA@LF at concentrations of 25, 50, 
100, 250 and 500 µg mL-1 (PSi or equivalent) in HBSS−HEPES (pH 7.4), AP at 
concentrations of 5, 10, 25, 50 and 100 µg mL-1 in HBSS−HEPES (pH 7.4), and free BUD, 
BUDAP@PSi-HA and BUDAP@PSi-HA@LF at concentrations f 5, 10, 20, 50 and 100 µg 
mL-1 (BUD or equivalent) in HBSS−HEPES (pH 7.4) were added to each well. After 
incubation for 24 h, the cells were washed twice with HBSS−HEPES (pH 7.4) and the number 
of viable cells was quantified using CellTiter-Glo® (Promega Corporation, USA). The 
luminescence was measured using Varioskan Flash plate re der (Thermo Fisher Scientific, 
USA). HBSS−HEPES (pH 7.4) and 1% of Triton X-100 were used as negative control and 
positive control, respectively. All the experiments were performed at least in triplicate. 
4.15. In vitro IBD model 
In vitro IBD model was modified from previous studies [47-49]. 6 × 104 Caco-2 clone cells 
were seeded into the apical compartment of 12-Transwell® plate, 1 × 104 macrophages and 1 
× 104 dendritic cells were seeded into the basolateral compartment. The co-culture was kept 
with Caco-2 medium (0.5 mL) in the apical compartment and macrophage medium (1.5 mL) 
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in the basolateral compartment, and the medium was ch nged every other day in both the 
apical and basolateral compartments. The co-culture was cultivated for 21 d to form cell 
monolayers. For the inflamed model, 0.5 mL Caco-2 medium with 20 ng mL-1 IL-1β 
(Peprotec, USA) and 0.1 µg mL-1 LPS was added to the apical compartment and incubated for 
2 d. 
4.16. Drug permeability across intestinal cell monolayers 
The permeability experiments were performed using i  vitro IBD model at 37 °C with 
shaking at 100 rpm, in comparison with healthy intestinal cell monolayers. After 2 d of 
cultivation with or without stimulation, the medium from the apical compartment was 
collected for dispersing the samples. 500 µL free BUD, BUD@PSi-HA@LF and 
BUDAP@PSi-HA@LF in apical medium were added into the apical compartment at a BUD 
(or equivalent) concentration of 50 µg mL-1. At specific time points (5, 15, 30, 60, 90, 120 
and 180 min), 100 µL sample were collected from the basolateral compartment and replaced 
with the same volume of fresh medium. The amount of permeated BUD in the basolateral 
compartment was quantified by HPLC, and the Papp was calculated, as described elsewhere 
[20]. The experiments were carried out in triplicate. 
4.17. In vitro treatment tests 
After 2 d of stimulation, both apical and basolaterl medium were removed, and cells were 
washed 3 times with PBS. Free BUD, BUD@PSi-HA@LF and BUDAP@PSi-HA@LF were 
added into the apical compartment, providing an equivalent BUD dose of 25 µg per well. 
After 4 h of incubation, which approximates drug retention time in the intestine of IBD 
patients [50], the apical medium was removed and replac d with fresh Caco-2 medium. The 
monolayers were used both for transepithelial electrical resistance (TEER) and IL-8 
measurements. IL-8 was quantified by enzyme-linked immunosorbent assay (ELISA) kits 
(BD Biosciences) according to the manufacturer's protocol. 
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4.18. Fluorescence labelling of nanoparticles 
FITC labelled PSi-SPM (PSi-FITC) and Cy7 labelled PSi-SPM (PSi-Cy7) were prepared by 
overnight stirring of 10 mg of PSi-SPM with 0.1 mg of FITC-NHS (Thermo Fisher Scientific, 
USA) and 0.1 mg of Cy7-NHS (Lumiprobe, Germany) in DMF, respectively. The obtained 
PSi-FITC and PSi-Cy7 were conjugated with HA using the EDC/NHS reaction as described 
above to produce FITC labelled PSi-HA (PSi-FITC/HA) and Cy7 labelled PSi-HA (PSi-
Cy7/HA), respectively. 
4.19. In vitro adhesion of nanoparticles 
FITC labelled PSi-HA were used for imaging in all in vitro adhesion experiments. Healthy 
and inflamed mucosa were simulated by coating Lab-Tek™ 8-chamber slides (Thermo Fisher 
Scientific, USA) or 96-well polystyrene plates (Corning, USA) with mucin from porcine 
stomach (Sigma-Aldrich, USA) and human transferrin (Sigma-Aldrich, USA), respectively 
[5]. Briefly, mucin solution (30 mg/mL in HBSS) was dded to the chamber slides/plates and 
incubated at room temperature for 2 h with gentle shaking. Transferrin solution (500 µg/ml in 
PBS) was added to the chamber slides/plates and incubated overnight at 37 °C. Chamber 
slides/plates incubated with PBS overnight at 37 °C were used as uncoated chamber 
slides/plates. After incubation, chamber slides/plates were washed with PBS for 3 times. FITC 
labelled BUDAP@PSi-HA were dispersed in PBS at a concentration of 50 µg/ml, and then 
added to each well of the chamber slides/plates. The chamber slides/plates were gently shaken 
at room temperature for 1 h. Wells were then washed with PBS for 3 times. The chamber 
slides were imaged using confocal microscope (Leica TCS SP5 II HCS A, Germany), and the 
fluorescence intensities of the plates were quantified using Varioskan™ LUX (Thermo Fisher 
Scientific, USA). 
In a second set of experiments, cationic branched polyethylenimine (PEI) (~25,000 g/mol, 
Sigma-Aldrich, USA) (10 mM, pH 4.0) was added to the FITC labelled BUDAP@PSi-HA to 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
28 
 
convert its surface charge from negative to positive, and the adhesion experiment was 
performed using uncoated-, mucin-coated, and transferrin-coated chamber slides/plates as 
described above. 
4.20. DSS-induced colitis model 
Male C57BL/6 mice (6-8 weeks) were purchased from Beijing Vital River Laboratory Animal 
Technology Co., Ltd. Mice were fed formulated drinking water containing 3% DSS (MW 36-
50 kDa; MP Biochemical, Hlkirch, France) ad libitum throughout the experiment (day 0 to 
day 14). The body weights of mice were monitored an the weights were recorded as 
percentage of initial bodyweight. Clinical evaluations including the assessment of stool 
consistency and the detection of rectal bleeding were conducted to generate a modified 
disease activity index (DAI) score. Briefly, each parameter was scored on a scale from 0 to 9 
and given a grade from 0 to 4 and then assessed as follows: (1) Stool consistency (0, well-
formed dry pellets; 1, soft pellets; 2, loose wet stools; 3, diarrhea; 4,massive watery stool at 
crissum ); (2) Fecal blood was tested with urine fecal occult blood test kit (Nanjing Jiancheng 
Bioengineering Institute, Nanjing China) (0, no color 2 min after adding the reagent; 1, the 
liquid gradually changed from light blue to blue within 30 s after adding the reagent; 2, the 
liquid was pale brown and gradually changed to clear blue-brown after adding the reagent 
within 10 s; 3, the liquid turn blue very quickly and a bit of blood was visible in the stool; 4, 
bloody stools, and the liquid turned into blue immediately; 5, the liquid was blue-brown 
immediately after adding the reagent and visibly bloody, with blood clotting on the anus and 
massive bleeding) [51]. 
4.21. In vivo adhesion experiments 
Animals with colitis and normal controls were fasted overnight before experiments. For in 
vivo adhesion testing, each mouse received 100 µL Milli-Q water containing 2 mg PSi-
Cy7/HA@LF or PSi-FITC/HA@LF by oral gavage. Milli-Q water rather than physiological 
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buffer solutions was used as vehicle due to the insolubility of LF in Milli-Q water. Animals 
were imaged at 2 and 5 h using IVIS Lumina II imaging system (PerkinElmer), and then 
immediately sacrificed after in vivo imaging. The colon was removed and imaged freshly after 
washing using IVIS Lumina II imaging system. The fluorescence signal intensity was 
quantified using Living Image software (PerkinElmer). For confocal imaging, the colon was 
washed with PBS for 3 times, and then embeds in tissue freezing medium for histologic 
section. Before confocal imaging, all the slices were stained by DAPI and F4/80 ab90247 to 
image the nucleus and macrophages, respectively. 
4.22. In vivo treatment of established colitis 
In vivo treatment experiments were performed using 10 groups: (1) disease-free control group 
(Normal), (2) colitis control group (Colitis), (3) free BUD, low dose (FBUDL), (4) free BUD, 
high dose (FBUDH), (5) AP@PSi-HA@LF particles, low dose (PL), (6) AP@PSi-HA@LF 
particles, high dose (PH), (7) BUD@PSi-HA@LF particles, low dose (BUDL), (8) 
BUD@PSi-HA@LF particles, high dose (BUDH), (9) BUDAP@PSi-HA@LF particles, low 
dose (BUDAPL), and (10) BUDAP@PSi-HA@LF particles, high dose (BUDAPH). Low 
dose and high dose were 0.5 mg/kg and 1.5 mg/kg BUD, respectively, or particles for the 
loading of 0.5 mg/kg and 1.5 mg/kg BUD, respectively. The vehicle for oral gavage was 100 
µL Milli-Q water. Oral gavage was performed daily, after fasting the mice overnight, for 7 d. 
During the treatment period, body weight was recorded, and DAI was evaluated. After 
treatment, mice were sacrificed and the colon was collected. The colonic length was measured. 
Then, standard H&E-stained sections of colon were prepared, examined and scored. For cell 
infiltration of inflammatory cells, rare inflammatory cells in the lamina propria were counted 
as 0; increased numbers of inflammatory cells, including neutrophils in the lamina propria as 
1; confluence of inflammatory cells, extending into the submucosa as 2; and a score of 3 was 
given for transmural extension of the inflammatory cell infiltrate. For epithelial damage, 
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absence of mucosal damage was counted as 0, discrete focal lymphoepithelial lesions were 
counted as 1, mucosal erosion/ulceration was counted as 2, and a score of 3 was given for 
extensive mucosal damage and extension through deeper structures of the bowel wall. The 
two subscores were added and the combined histologic score ranged from 0 (no changes) to 6 
(extensive cell infiltration and tissue damage) [5, 52  53]. 
TUNEL assay was performed according to the manufactrer's instruction, using the 
DeadEndTM TUNEL System Kit (G3250, Promega, Wisconsin, USA).  
The blood samples were collected within orbital plexus, and centrifuged at 3000 rpm at 4 °C 
for 10 min to obtain serum. Blood serum sample was used to measure the levels of IL-1β and 
IL-6 with commercial ELISA kits. 
All animal experiments were approved by the Animal C re and Use Committee of Xiamen 
University (China), and all protocols of animal studies conformed to the Guide for the Care 
and Use of Laboratory Animals. 
4.23. Statistical analysis 
All results were expressed as mean ± standard deviation (SD). A one-way analysis of variance 
(ANOVA) followed by the Bonferroni post hoc test was employed to analyze the data. The 
analysis was performed using OriginPro 9.0.0 software (OriginLab Corporation, USA) and 
the level of significance was set at the probabilities of *p < 0.05, **p < 0.01 and ***p < 0.001. 
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